HIMS250110P31000
- 6.25
- +2.13+51.70%
Hims & Hers Health Newsroom
Hims & Hers Health Analyst Ratings
Citi Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Raises Target Price to $25
BTIG Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $35
Needham Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $31
Hims & Hers Health Is Maintained at Buy by Needham
Hims & Hers Health Analyst Ratings
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $42
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Issues a Hold Rating on Hims & Hers Health (HIMS)
Hims & Hers Health: Sell Rating Due to Compounding Exemption Risks and Uncertain GLP-1 Contributions
Hims & Hers Health Initiated at Overweight by Morgan Stanley
Hims & Hers Health Analyst Ratings
Morgan Stanley Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $42
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Gives a Hold Rating to Hims & Hers Health (HIMS)
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Hims & Hers Health: Buy Rating Backed by Promising Growth in GLP-1 Market and Strong Telehealth Positioning
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $38